ESMO® 2025 Highlights: Presenter Vignette – Jeremie Calais
Jeremie Calais
MD PhD
David Geffen School of Medicine at UCLA
LBA90
Prospective Randomized Phase 2 trial of 177Lutetium-PSMA therapy Neoadjuvant to Stereotactic Ablative Radiotherapy for recurrent Oligo-Metastatic Hormone-Sensitive Prostate Cancer (LUNAR NCT05496959)
What is next after clinical trials testing PSMA & lutetium?
